Past, present, and future challenges in breast cancer treatment.
作者信息
Sledge George W, Mamounas Eleftherios P, Hortobagyi Gabriel N, Burstein Harold J, Goodwin Pamela J, Wolff Antonio C
机构信息
Stanford University School of Medicine, Stanford, CA
University of Florida Health Cancer Center, Orlando, FL.
出版信息
J Clin Oncol. 2014 Jul 1;32(19):1979-86. doi: 10.1200/JCO.2014.55.4139. Epub 2014 Jun 2.
Abstract
摘要
相似文献
1
Past, present, and future challenges in breast cancer treatment.乳腺癌治疗中的过去、现在和未来挑战。
J Clin Oncol. 2014 Jul 1;32(19):1979-86. doi: 10.1200/JCO.2014.55.4139. Epub 2014 Jun 2.
2
Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.与HER2、Ki-67、p53和bcl-2相比，两个周期后的临床反应在独立预测可手术乳腺癌患者术前化疗后的病理完全缓解方面的作用。
Breast Cancer Res. 2008;10(2):R30. doi: 10.1186/bcr1989. Epub 2008 Apr 1.
3
[Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer. Its relation with molecular subtypes].[新辅助化疗后乳腺癌前哨淋巴结活检及其与分子亚型的关系]
Rev Esp Med Nucl Imagen Mol. 2014 Nov-Dec;33(6):340-5. doi: 10.1016/j.remn.2014.04.003. Epub 2014 May 21.
4
c-erbB-2 and the "triple-state" in early breast carcinomas.c-erbB-2 与早期乳腺癌的“三重状态”。
Med Oncol. 2010 Sep;27(3):578-84. doi: 10.1007/s12032-009-9252-6. Epub 2009 Jun 23.
5
The triple-negative subtype: new ideas for the poorest prognosis breast cancer.三阴性亚型：针对预后最差的乳腺癌的新见解。
J Natl Cancer Inst Monogr. 2011;2011(43):108-10. doi: 10.1093/jncimonographs/lgr038.
6
[New approaches to the treatment of breast cancer].[乳腺癌治疗的新方法]
Vopr Onkol. 2013;59(3):288-91.
7
Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.分子亚型作为新辅助治疗乳腺癌局部和远处复发的预测指标。
Oncology. 2011;80(5-6):341-9. doi: 10.1159/000330203. Epub 2011 Jul 26.
8
The actual scenario of neoadjuvant chemotherapy of breast cancer in developing country: a report of 80 cases of breast cancer from a tertiary cancer center in India.发展中国家乳腺癌新辅助化疗的实际情况：来自印度一家三级癌症中心的 80 例乳腺癌报告。
J Cancer Res Clin Oncol. 2014 Oct;140(10):1777-82. doi: 10.1007/s00432-014-1724-1. Epub 2014 Jun 4.
9
[Modern pharmacological therapy of breast cancer].[乳腺癌的现代药物治疗]
Orv Hetil. 2012 Jan 15;153(2):56-65. doi: 10.1556/OH.2012.29257.
10
Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management?新辅助化疗前后的乳腺癌生物标志物：重复检测是否会影响治疗管理？
Hum Pathol. 2017 Apr;62:215-221. doi: 10.1016/j.humpath.2016.12.019. Epub 2016 Dec 30.
引用本文的文献
1
Efficacy of urolithin B-Loaded mesoporous silica nanoparticles modified with graphene quantum Dots against MCF-7 breast Cancer cells.负载尿石素B的石墨烯量子点修饰介孔二氧化硅纳米粒子对MCF-7乳腺癌细胞的疗效
Sci Rep. 2025 Jul 15;15(1):25473. doi: 10.1038/s41598-025-10904-3.
2
Bioactivity Profiling of Chemically Characterized Extract of Saudi Jackfruit () Using In Vitro and In Silico Approaches.采用体外和计算机模拟方法对沙特菠萝蜜化学特征提取物进行生物活性分析
Scientifica (Cairo). 2025 Jun 22;2025:8015648. doi: 10.1155/sci5/8015648. eCollection 2025.
3
Targeting monopolar spindle kinase I (Mps1 or TTK) induces radiosensitization in syngeneic models of triple negative breast cancer (TNBC) and potentiates type I interferon (T1IFN) signaling.靶向单极纺锤体激酶I（Mps1或TTK）可在三阴性乳腺癌（TNBC）的同基因模型中诱导放射增敏作用，并增强I型干扰素（T1IFN）信号传导。
Neoplasia. 2025 Aug;66:101190. doi: 10.1016/j.neo.2025.101190. Epub 2025 Jun 9.
4
Plant-based exosome-like extracellular vesicles as encapsulation vehicles for enhanced bioavailability and breast cancer therapy: recent advances and challenges.基于植物的外泌体样细胞外囊泡作为增强生物利用度和乳腺癌治疗的封装载体：最新进展与挑战
Med Oncol. 2025 Apr 28;42(6):184. doi: 10.1007/s12032-025-02720-6.
5
Clinical significance of FOXN3 expression in Indian breast cancer patients.FOXN3表达在印度乳腺癌患者中的临床意义。
Sci Rep. 2025 Apr 18;15(1):13414. doi: 10.1038/s41598-025-98090-0.
6
Advances in analytical approaches for background parenchymal enhancement in predicting breast tumor response to neoadjuvant chemotherapy: A systematic review.用于预测乳腺肿瘤对新辅助化疗反应的背景实质强化分析方法的进展：一项系统综述。
PLoS One. 2025 Mar 7;20(3):e0317240. doi: 10.1371/journal.pone.0317240. eCollection 2025.
7
Role of universal health coverage in improving quality of breast cancer care: an international comparison study.全民健康覆盖在改善乳腺癌护理质量中的作用：一项国际比较研究。
BMJ Public Health. 2024 Sep 24;2(2):e000863. doi: 10.1136/bmjph-2023-000863. eCollection 2024 Dec.
8
Recent advancements in nanomaterial-based biosensors for diagnosis of breast cancer: a comprehensive review.基于纳米材料的乳腺癌诊断生物传感器的最新进展：综述
Cancer Cell Int. 2025 Feb 18;25(1):50. doi: 10.1186/s12935-025-03663-8.
9
Lucidin from Outperforms FDA-Approved Lapatinib as a Potential Multitargeted Candidate for Breast Cancer Signalling Proteins.与美国食品药品监督管理局（FDA）批准的拉帕替尼相比，来自[具体来源]的卢西定作为乳腺癌信号蛋白的潜在多靶点候选物表现更优。
Pharmaceuticals (Basel). 2025 Jan 9;18(1):68. doi: 10.3390/ph18010068.
10
Recurrence Patterns and Long-Term Results After Curative Surgery for Patients With Breast Cancer.乳腺癌患者根治性手术后的复发模式及长期结果
Ann Surg Oncol. 2025 Apr;32(4):2554-2568. doi: 10.1245/s10434-024-16726-3. Epub 2024 Dec 30.
本文引用的文献
1
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.阿那曲唑预防绝经后高危女性乳腺癌（IBIS-II）：一项国际、双盲、随机、安慰剂对照试验。
Lancet. 2014 Mar 22;383(9922):1041-8. doi: 10.1016/S0140-6736(13)62292-8. Epub 2013 Dec 12.
2
The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.磷脂酰肌醇-3-激酶-Akt-哺乳动物雷帕霉素靶蛋白通路作为乳腺癌的治疗靶点。
J Natl Compr Canc Netw. 2013 Jun 1;11(6):670-8. doi: 10.6004/jnccn.2013.0086.
3
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.腋窝清扫与前哨淋巴结微转移患者不进行腋窝清扫（IBCSG 23-01）：一项 3 期随机对照试验。
Lancet Oncol. 2013 Apr;14(4):297-305. doi: 10.1016/S1470-2045(13)70035-4. Epub 2013 Mar 11.
4
Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis.三阴性乳腺癌中铂类化疗的荟萃分析。
Oncol Lett. 2013 Mar;5(3):983-991. doi: 10.3892/ol.2012.1093. Epub 2012 Dec 28.
5
Molecular characterization of basal-like and non-basal-like triple-negative breast cancer.基底样和非基底样三阴性乳腺癌的分子特征。
Oncologist. 2013;18(2):123-33. doi: 10.1634/theoncologist.2012-0397. Epub 2013 Feb 12.
6
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.辅助多西他赛、多柔比星和环磷酰胺治疗淋巴结阳性乳腺癌：III 期随机 BCIRG 001 试验的 10 年随访结果。
Lancet Oncol. 2013 Jan;14(1):72-80. doi: 10.1016/S1470-2045(12)70525-9. Epub 2012 Dec 12.
7
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.雌激素受体阳性乳腺癌诊断后继续辅助他莫昔芬治疗 10 年与 5 年后停药的长期疗效：ATLAS，一项随机试验。
Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1.
8
Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update.原发性治疗后的乳腺癌随访和管理：美国临床肿瘤学会临床实践指南更新。
J Clin Oncol. 2013 Mar 1;31(7):961-5. doi: 10.1200/JCO.2012.45.9859. Epub 2012 Nov 5.
9
Trastuzumab emtansine for HER2-positive advanced breast cancer.曲妥珠单抗-美坦新偶联物用于治疗人表皮生长因子受体 2 阳性的晚期乳腺癌。
N Engl J Med. 2012 Nov 8;367(19):1783-91. doi: 10.1056/NEJMoa1209124. Epub 2012 Oct 1.
10
Comprehensive molecular portraits of human breast tumours.人类乳腺肿瘤的全面分子特征图谱。
Nature. 2012 Oct 4;490(7418):61-70. doi: 10.1038/nature11412. Epub 2012 Sep 23.
Zotero 插件